


SUPPLEMENTARY MATERIALS

Table S1 List of primers used for qRT-PCR

Gene names	Primer	Sequence
Mouse <i>Neu1</i>	Forward	5'-CGAATTGTCCTCCGCAGCTA-3'
Mouse <i>Neu1</i>	Reversed	5'-TCCGCCATGAGGTACCATTG-3'
Mouse <i>Acp5</i>	Forward	5'-AGACGAGGTTACGCTGTGC-3'
Mouse <i>Acp5</i>	Reversed	5'-TCGGGGACAATTCGGTAAACT-3'
Mouse <i>Ctsk</i>	Forward	5'- GCGGCATTACCAACAT -3'
Mouse <i>Ctsk</i>	Reversed	5'- CTGGAAGCACCAACGA -3'
Mouse <i>Nfatc1</i>	Forward	5'-GAGGAGTTGGCTCAGTG-3'
Mouse <i>Nfatc1</i>	Reversed	5'-TAGCGTTCCGTTTCGTT-3'
Mouse <i>OCstamp</i>	Forward	5'- TTATGTGTTTCCACGAAGCCCTA -3'
Mouse <i>OCstamp</i>	Reversed	5'- ACAGAAGAGAGCAGGGCAACG -3'
Mouse <i>Pdgfb</i>	Forward	5'-CATCCGCTCCTTTGATGATCTT -3'
Mouse <i>Pdgfb</i>	Reversed	5'-GTGCTCGGGTCATGTTCAAGT -3'
Mouse <i>St3gal1</i>	Forward	5'- TCCAACACGGGAGTACCCA -3'
Mouse <i>St3gal1</i>	Reversed	5'- GCTGGTCGAACCAATATGATACC -3'
Mouse <i>St6gal1</i>	Forward	5'-CTCCTGTTTGCCATCATCTGC -3'
Mouse <i>St6gal1</i>	Reversed	5'-GGGTCTTGTTTGCTGTTTGAGA -3'
Mouse <i>Gapdh</i>	Forward	5'- AACGTCGGAACGATAGCA -3'
Mouse <i>Gapdh</i>	Reversed	5'- CTTAAGGCTAGTTAGGCCC -3'

1 **Figure S1**



2

3 **Figure S1.** NEU3 IHC score of periosteum and bone marrow; n=3;

4

Figure S2




Figure S2. Schematic of Siglec15 mediating osteoclast recognition and fusion by binding to α -2,3 sialylated TLR2.

Figure S3





Image source : Ce Dou., et al., *Sialylation of TLR2 initiates osteoclast fusion*. *Bone Res*, 2022 Mar 2;10(1):24.

Figure S3. Sialic acid A-2,3 mediates the fusion of mononuclear osteoclasts.

- (A) Immunoblotting (IB) for TLR2 in whole-cell lysates or protein complexes immunoprecipitated (IP) with Siglec15 in *Siglec15^{ΔLysM}* or *Siglec15^{fl/fl}* (WT) BMMs to test the effects of sialidase.
- (B) IB for DAP12 in whole-cell lysates or protein complexes IP with Siglec15 and IB for Siglec15 in whole-cell lysates or protein complexes IP with DAP12 in the indicated groups.
- (C) IB for DAP12 and Syk in whole-cell lysates or protein complexes IP with p-Tyr in the indicated groups.
- (D) IB for MyD88 in protein complexes IP with TLR2 in the indicated groups. IB for TLR2, NFATc1, and Siglec15 in whole-cell lysates.

1 **Figure S4**



2
3 **Figure S4.** Clusters of cells that has passed through a reduced-dimension cluster
4

Figure S5





Figure S5. Differentially expressed genes (DEGs) of each cluster were identified with the Wilcoxon rank-sum test.

1 **Figure S6**



2

3 **Figure S6.** Immunofluorescence staining showed the inhibitory effect of fibroblast conditioned
 4 medium on the sialylation of osteoclasts (α-2,6 SA).

Figure S7




Figure S7. Oseltamivir effectively inhibits NEU1 activity and increases sialic acid levels in bone tissue

Figure S8




Figure S8. Expression level of NEU1 in callus at different stages of fracture healing.

Figure S9




Figure S9. (A) Feature Plot shows the distribution characteristics of marker genes in various cell subpopulations. Among these, the original authors consider *ZsGreen*⁺, *Dpt*⁺, *Cd34*⁺, and *Pi16* as markers for the periosteal fibrous layer, while *tdTomato*⁺ and *Postn*⁺ are markers for the periosteal cambium layer. (B) Violin plots show that there is expression consistency between the high-expression subpopulations of *Neu1* and *Pi16* (the fibroblast marker gene identified by the original authors).

Figure S10




Figure S10. (A) Relative expression of *NEU1* mRNA in fibroblasts treated with vehicle, control siRNA (*si-NC*), or Neu1-targeting siRNA (*si-Neu1*), normalized to *Gapdh*, n = 3; (B) Representative TRAP staining images of osteoclasts cultured in conditioned medium produced by fibroblasts treated with vehicle, *si-NC*, or *si-Neu1*, scale bar = 200 μm; (C) Quantification of osteoclasts per well in different treatment group, n = 5;

Figure S11




Figure S11. (A) Representative micro-CT images show cortical and trabecular bone of OVX model mice after treatment with vehicle or NEU1 homologous protein for 4 weeks; BV/TV (Bone bone volume fraction) analysis of trabeculae bone in both groups, n = 4. (B) Representative micro-CT images showing callus of fracture mice after treatment with vehicle or recombinant NEU1 for 4 weeks, quantification of CV (callus volume) from each group, n = 5;